Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa.

ABSTRACT:

Background

Dexamethasone and remdesivir have the potential to reduce coronavirus disease 2019 (COVID)-related mortality or recovery time, but their cost-effectiveness in countries with limited intensive care resources is unknown.

Methods

We projected intensive care unit (ICU) needs and capacity from August 2020 to January 2021 using the South African National COVID-19 Epi Model. We assessed the cost-effectiveness of (1) administration of dexamethasone to ventilated patients and remdesivir to nonventilated patients, (2) dexamethasone alone to both nonventilated and ventilated patients, (3) remdesivir to nonventilated patients only, and (4) dexamethasone to ventilated patients only, all relative to a scenario of standard care. We estimated costs from the health care system per

SUBMITTER: Jo Y 

PROVIDER: S-EPMC7928624 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature